Scholarlink

<p>Digital health applications (DHA) can provide exercise therapy, behavioral interventions or patient education. These interventions are of high relevance in axial spondyloarthritis (axSpA). Therefore, axSpA represents a&#xa0;potentially promising area of DHA usage; however, no DHA has yet been officially approved for axSpA. Currently, the medical apps <i>Axia</i> and <i>RheCORD Plus</i> are in the DiGA approval track. So far, published study results are only available for <i>Axia</i> and appear promising. In addition to these apps, DHAs such as <i>ViViRA</i> or <i>HelloBetter Chronic Pain</i> are being tested in axSpA, and initial study results also show positive effects in this context. The use of DHAs in axSpA thus shows promising potential, although further research is needed to evaluate long-term effectiveness, cost-effectiveness and user acceptance.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Digitale Gesundheitsanwendungen und axiale Spondyloarthritis

  • 期刊论文

  • 发表日期：

    2025年10月10日

查看全文
  • Patrick-Pascal Strunz,
  • Uta Kiltz,
  • David Kiefer,
  • Marc Schmalzing

摘要

Digital health applications (DHA) can provide exercise therapy, behavioral interventions or patient education. These interventions are of high relevance in axial spondyloarthritis (axSpA). Therefore, axSpA represents a potentially promising area of DHA usage; however, no DHA has yet been officially approved for axSpA. Currently, the medical apps Axia and RheCORD Plus are in the DiGA approval track. So far, published study results are only available for Axia and appear promising. In addition to these apps, DHAs such as ViViRA or HelloBetter Chronic Pain are being tested in axSpA, and initial study results also show positive effects in this context. The use of DHAs in axSpA thus shows promising potential, although further research is needed to evaluate long-term effectiveness, cost-effectiveness and user acceptance.